Wiener klinische Wochenschrift

, Volume 131, Issue 1–2, pp 8–16 | Cite as

Burden of disease in patients with chronic hepatitis C in the Austrian REAL study

  • Michael GschwantlerEmail author
  • Thomas Bamberger
  • Ivo Graziadei
  • Andreas Maieron
  • Nives Katalinic
  • Rudolf Stauber
original article



The direct-acting antiviral regimen of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) is approved to treat patients with chronic hepatitis C (CHC) infection genotypes 1 or 4, including compensated cirrhosis. The aim of the prospective, multicenter, observational REAL study was to provide evidence of the effectiveness of this regimen in an Austrian real-world setting and to determine the impact on patient-reported outcomes (PROs).


Effectiveness was defined as sustained virologic response 12 weeks after the end of treatment (SVR12). EuroQol 5 Dimension 5 Level (EQ-5D-5L) and Work Productivity and Activity Impairment HepC v2.0 (WPAI) questionnaires were used to assess PROs.


A total of 173 patients were enrolled. The SVR12 was 95.9% (140/146) in the core population with sufficient follow-up (i. e. patients without SVR12 data not due to efficacy/safety reasons, such as lost to follow-up, were excluded) and 84.8% (140/165) in the core population (CP). Data at all timepoints for the EQ-5D-5L index score and visual analog scale and the total activity impairment score of the WPAI were available for 88, 95 and 72 patients, respectively. All PROs remained generally unaltered during treatment with OBV/PTV/r ± DSV ± RBV but showed a statistically significant (p < 0.01) improvement 12 weeks after the end of treatment versus baseline.


These are the first data on PROs in a real-world setting with OBV/PTV/r ± DSV ± RBV treatment; this study demonstrated that treatment did not negatively impact quality of life. Results from the Austrian REAL study support the effectiveness of OBV/PTV/r ± DSV ± RBV in patients with CHC genotype 1 and 4 in everyday clinical practice.


Chronic hepatitis C Dasabuvir Ombitasvir/paritaprevir/ritonavir Direct-acting antivirals Patient-reported outcome measures 



Statistical support was provided by Ina Burghaus, PhD, of Prometris GmbH, Mannheim, Germany, and medical writing support was provided by Ulrike Hauf-Zachariou, MD, of IST GmbH, Mannheim, Germany, both funded by AbbVie. The authors would like to express their gratitude to the study participants, investigators, and coordinators who made this study possible.

Compliance with ethical guidelines

Conflict of interest

AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the manuscript. All authors had access to all relevant data. M. Gschwantler: advisor for AbbVie, Gilead, BMS, MSD, and Janssen; received speaker fees from AbbVie, Gilead, BMS, MSD, and Janssen; grants from AbbVie, Gilead and MSD. T. Bamberger: advisor for AbbVie, BMS, and MSD; received speaker fees from AbbVie, Gilead, and BMS. I. Graziadei: advisory board: AbbVie, Gilead, BMS, MSD, and Janssen; received speaker fees from AbbVie, Gilead, BMS, and MSD. A. Maieron: advisor for AbbVie, Gilead, BMS, MSD, and Janssen; received speaker fees from AbbVie, Gilead, BMS, MSD, and Janssen. N. Katalinic: AbbVie employee and may hold AbbVie stock or options. R. Stauber: advisor for AbbVie, BMS, Gilead, and MSD; received speaker fees from AbbVie, BMS, and Gilead; and research grant from AbbVie.

Ethical standards

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all patients included in the study.


  1. 1.
    WHO. 69th World Health Assembly 2016, document A69/32. 2016. Accessed 29 Mar 2018.Google Scholar
  2. 2.
    AbbVie GmbH & Co. KG (2018) Viekirax—Summary of Product Characteristics [accessed March 12, 2018]. Available from:
  3. 3.
    Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–603.CrossRefGoogle Scholar
  4. 4.
    Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–14.CrossRefGoogle Scholar
  5. 5.
    Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;47:359–65.CrossRefGoogle Scholar
  6. 6.
    Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–92.CrossRefGoogle Scholar
  7. 7.
    Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82.CrossRefGoogle Scholar
  8. 8.
    Hezode C, Marcellin P, Pol S, et al. Results from the phase 2 PEARL-I study: interferon-free regimens of ABT-450/R + ABT-267 with or without ribavirin in patients with HCV genotype 4 infection. J Hepatol. 2014;60(suppl 1):24.CrossRefGoogle Scholar
  9. 9.
    Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol. 2016;64:301–7.CrossRefGoogle Scholar
  10. 10.
    Asselah T, Hézode C, Qaqish RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet Gastroenterol Hepatol. 2016;1:25–35.CrossRefGoogle Scholar
  11. 11.
    Waked I, Shiha G, Qaqish RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol. 2016;1:36–44.CrossRefGoogle Scholar
  12. 12.
    Marley J. Efficacy, effectiveness, efficiency. Aust Prescr. 2000;23:114–5.CrossRefGoogle Scholar
  13. 13.
    Marcellin F, Roux P, Protopopescu C, et al. Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Rev Gastroenterol Hepatol. 2017;11(3):259–68.PubMedGoogle Scholar
  14. 14.
    Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.CrossRefGoogle Scholar
  15. 15.
    Reilly Associates. Health outcomes research WPAI. 2002. Accessed 12 Mar 2018.Google Scholar
  16. 16.
    Kozbial K, Aberle S, Susser S, et al. Retreatment of patients with chronic hepatitis C who failed interferon-free combination therapy with direct acting antivirals. Aliment Pharmacol Ther. 2017;45:373–9.CrossRefGoogle Scholar
  17. 17.
    Welzel TM, Hinrichsen H, Sarrazin C, et al. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. J Viral Hepat. 2017;24:840–9.CrossRefGoogle Scholar
  18. 18.
    Zuckerman E, Ashkenasi E, Kovalev Y, et al. The real-world Israeli experience of treating chronic hepatitis C, genotype 1 patients with advanced fibrosis with paritaprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin: a large multi-center cohort. J Hepatol. 2016; Scholar
  19. 19.
    Calleja JL, Rincon D, Ruiz-Antoran B, et al. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir and dasabuvir patients with genotype 1 chronic hepatitis C virus infection: results from the Spanish real world cohort. J Hepatol. 2016; Scholar
  20. 20.
    Saab S, Mehta D, Hudgens S, et al. Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C. Liver Int. 2018;38(8):1377–94. Scholar
  21. 21.
    Younossi ZM, Stepanova M, Asselah T, et al. Hepatitis C in patients with minimal or no hepatic fibrosis: the impact of treatment and sustained virologic response on patient-reported outcomes. Clin Infect Dis. 2017; Scholar
  22. 22.
    Stepanova M, Thompson A, Doyle J, et al. Hepatitis C virus-infected patients receiving opioid substitution therapy experience improvement in patient-reported outcomes following treatment with interferon-free regimens. J Infect Dis. 2018;217(7):1033–43. Scholar
  23. 23.
    Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health related quality of life in chronic hepatitis C. J Hepatol. 2004;40(4):675–81.CrossRefGoogle Scholar
  24. 24.
    Arora S, O’Brien C, Zeuzem S, et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol. 2006;21(2):406–12.CrossRefGoogle Scholar
  25. 25.
    Dore GJ, Conway B, Luo Y, et al. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I/II trials. J Hepatol. 2016;64(1):19–28.CrossRefGoogle Scholar
  26. 26.
    Buggisch P, Link R, Naumann U, et al. Quality of life in HCV patients treated with ombitasvir/paritaprevir/r + dasabuvir + ribavirin under real-life conditions—data from the German observational study LIFE-C. Hepatology. 2017;66:1541. The Liver Meeting 2017; October 20–24, 2017; Washington, DC, USA (abstract 1541).Google Scholar
  27. 27.
    Younossi ZM, Stepanova M, Gane EJ, et al. Significant and sustained improvement of health-related quality of life (HRQL) scores in patients with hepatitis C (HCV) and sustained virologic response (SVR). Hepatology. 2017;66:64. The Liver Meeting 2017; October 20–24, 2017; Washington, DC, USA (abstract 64).Google Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Medicine IVWilhelminen HospitalViennaAustria
  2. 2.Department of Internal Medicine IIKepler University HospitalLinzAustria
  3. 3.Department of Internal MedicineAcademic Teaching HospitalHallAustria
  4. 4.Department of Internal Medicine 4, Gastroenterology & HepatologyElisabethinen HospitalLinzAustria
  5. 5.AbbVie GmbHViennaAustria
  6. 6.Department of Internal MedicineMedical University of GrazGrazAustria
  7. 7.Sigmund Freud UniversityViennaAustria
  8. 8.Department of Internal MedicineGESPAG KH SchärdingSchärdingAustria
  9. 9.Department of Internal Medicine 4, Gastroenterology & HepatologyUniversity Clinic, St. PöltenSt. PöltenAustria

Personalised recommendations